ClariTrial | Search Clinical Trials

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

162 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

Dabigatran Versus Apixaban in Cerebral Venous Thrombosis

Phase 3Cerebral Venous Sinus Thrombosis

Dabigatran Etexilate 150mgApixaban 5MG

Kafrelsheikh University200 participants1 site · EgyptCompletes Sep 2024

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Phase 3Alzheimer Disease

KarXTPlacebo

Karuna Therapeutics, Inc., a Bristol Myers Squibb company406 participants281 sites · United States, Argentina, BelgiumCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

PET Tau - Neurodegenerative Disease Imaging

Phase 2Phase 3Neurodegenerative Disease

18F-AV-1451

University of Pennsylvania300 participants1 site · United StatesCompletes Sep 2030

Compare CT.gov Full analysis →

Recruiting

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Phase 2Parkinson Disease

BIIB122 225 mgBIIB122-Matching Placebo

Denali Therapeutics Inc.50 participants20 sites · United States, Germany, IsraelCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial

Phase 2Chronic Migraine

MPL-001

University of Manitoba20 participants3 sites · CanadaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

Phase 3Huntington Disease

Votoplam (blinded)Placebo

Novartis Pharmaceuticals770 participants4 sites · United States, CanadaCompletes Apr 2030

Compare CT.gov Full analysis →

Recruiting

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Phase 3Dravet Syndrome

Clemizole HClPlacebo

Epygenix150 participants46 sites · United States, Canada, GeorgiaCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

High Dose Steroids in Children With Stroke

Phase 3Paediatric Stroke

MethylprednisolonePrednisolone

Insel Gruppe AG, University Hospital Bern70 participants35 sites · Australia, Austria, DenmarkCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Phase 2Phase 3Alzheimers DiseaseDementiaAlzheimers Disease, Familial

Remternetug (SC)Matching Placebo (Remternetug)

Washington University School of Medicine280 participants35 sites · United States, Argentina, AustraliaCompletes Mar 2034

Compare CT.gov Full analysis →

Recruiting

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)

Ocrelizumab (US)Ocrelizumab (EU)ABP 692

Amgen444 participants107 sites · United States, Belgium, BulgariaCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke

Phase 3Ischemic Stroke

Atorvastatin 40 Mg Oral TabletRosuvastatin 20mgClopidogrel 75 Mg Oral Tablet+1 more

Kafrelsheikh University600 participants1 site · EgyptCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

Phase 2Cerebral Amyloid AngiopathyIntracerebral Hemorrhage Lobar

Colchicine 0.5mgMatching placebo

Huashan Hospital80 participants3 sites · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

Phase 1Phase 2Canavan Disease

AAV9 BBP-812

Aspa Therapeutics26 participants4 sites · United StatesCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Phase 3Alzheimer Disease

Combined metabolic activatorsCollagen and maltodextrin

ScandiBio Therapeutics AB845 participants8 sites · Turkey (Türkiye)Completes Sep 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Phase 3Ischemic Stroke; Ischemic Attack, Transient

MilvexianPlacebo

Janssen Research & Development, LLC15,000 participants880 sites · United States, Argentina, AustraliaCompletes Nov 2026

Compare CT.gov Full analysis →

1–15 of 162

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

162 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

Dabigatran Versus Apixaban in Cerebral Venous Thrombosis

Phase 3Cerebral Venous Sinus Thrombosis

Dabigatran Etexilate 150mgApixaban 5MG

Kafrelsheikh University200 participants1 site · EgyptCompletes Sep 2024

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Phase 3Alzheimer Disease

KarXTPlacebo

Karuna Therapeutics, Inc., a Bristol Myers Squibb company406 participants281 sites · United States, Argentina, BelgiumCompletes Sep 2026

Compare CT.gov Full analysis →

Recruiting

PET Tau - Neurodegenerative Disease Imaging

Phase 2Phase 3Neurodegenerative Disease

18F-AV-1451

University of Pennsylvania300 participants1 site · United StatesCompletes Sep 2030

Compare CT.gov Full analysis →

Recruiting

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Phase 2Parkinson Disease

BIIB122 225 mgBIIB122-Matching Placebo

Denali Therapeutics Inc.50 participants20 sites · United States, Germany, IsraelCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial

Phase 2Chronic Migraine

MPL-001

University of Manitoba20 participants3 sites · CanadaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

Phase 3Huntington Disease

Votoplam (blinded)Placebo

Novartis Pharmaceuticals770 participants4 sites · United States, CanadaCompletes Apr 2030

Compare CT.gov Full analysis →

Recruiting

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Phase 3Dravet Syndrome

Clemizole HClPlacebo

Epygenix150 participants46 sites · United States, Canada, GeorgiaCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

High Dose Steroids in Children With Stroke

Phase 3Paediatric Stroke

MethylprednisolonePrednisolone

Insel Gruppe AG, University Hospital Bern70 participants35 sites · Australia, Austria, DenmarkCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Phase 2Phase 3Alzheimers DiseaseDementiaAlzheimers Disease, Familial

Remternetug (SC)Matching Placebo (Remternetug)

Washington University School of Medicine280 participants35 sites · United States, Argentina, AustraliaCompletes Mar 2034

Compare CT.gov Full analysis →

Recruiting

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)

Ocrelizumab (US)Ocrelizumab (EU)ABP 692

Amgen444 participants107 sites · United States, Belgium, BulgariaCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke

Phase 3Ischemic Stroke

Atorvastatin 40 Mg Oral TabletRosuvastatin 20mgClopidogrel 75 Mg Oral Tablet+1 more

Kafrelsheikh University600 participants1 site · EgyptCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

Phase 2Cerebral Amyloid AngiopathyIntracerebral Hemorrhage Lobar

Colchicine 0.5mgMatching placebo

Huashan Hospital80 participants3 sites · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

Phase 1Phase 2Canavan Disease

AAV9 BBP-812

Aspa Therapeutics26 participants4 sites · United StatesCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Phase 3Alzheimer Disease

Combined metabolic activatorsCollagen and maltodextrin

ScandiBio Therapeutics AB845 participants8 sites · Turkey (Türkiye)Completes Sep 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Phase 3Ischemic Stroke; Ischemic Attack, Transient

MilvexianPlacebo

Janssen Research & Development, LLC15,000 participants880 sites · United States, Argentina, AustraliaCompletes Nov 2026

Compare CT.gov Full analysis →

1–15 of 162